Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Exploring the underlying mechanIsms of partial leptin reduction towards a non-invasive obesity therapy

Descripción del proyecto

Estudio de los efectos de la leptinoterapia para frenar el aumento excesivo de peso

La obesidad ha aumentado de forma peligrosa en muchos países del mundo. La Organización Mundial de la Salud advierte que la obesidad ha alcanzado proporciones epidémicas a nivel mundial. Hace más de veintiséis años, varios estudios sugirieron que los tratamientos con leptina (que regula el balance energético al funcionar como una «señal de saciedad») podrían emplearse para el tratamiento de la obesidad. Sin embargo, las pruebas no tuvieron éxito. El proyecto financiado con fondos europeos MILER estudiará por qué. En concreto, se dilucidarán los mecanismos moleculares subyacentes que son inducidos por la reducción de la leptina sérica y desencadenan la resensibilización a la leptina. También se investigará si la reducción de la leptina sérica tienen efectos sinérgicos con los métodos de pérdida de peso existentes.

Objetivo

Leptin regulates energy balance by functioning as a “satiety signal”. When identified 26 years ago, expectations were high that leptin therapies could be used for the treatment of obesity. In contrast to the successful use of leptin for treatment of individuals with lipodystrophy and complete leptin deficiency, pharmacological approaches using leptin therapy for the treatment of diet-induced obesity have been widely unsuccessful. Injecting recombinant leptin in the context of obesity, associated with elevated leptin levels, remains ineffective as central neurons become leptin resistant. Interestingly, Scherer et al. recently published a series of findings that encourages for a conceptual shift. They reported that a partial reduction of circulating leptin levels in the obese state prompts an unexpected systemic response resulting in weight loss, reduced food intake, improved glucose and insulin tolerance and increased energy expenditure - all consistent with leptin re-sensitization in central neurons. The systemic physiological benefits of partial leptin reduction have already been demonstrated. The overall goal of this proposal is therefore to determine the underlying molecular mechanisms that are induced by leptin reduction and trigger leptin re-sensitization. Understanding of these conceptual steps should lead us to explore partial leptin reduction as a viable avenue for anti-obesity and anti-diabetic therapy in the near future. We aim to determine the peripheral effects of leptin reduction using neutralizing leptin antibodies and advanced mouse genetics. Moreover, we will determine downstream signaling events that are affected in peripheral tissues upon leptin depletion using imaging mass cytometry and transcriptional regulation by single cell RNAseq. Finally, we will also determine whether leptin lowering offers synergistic effects with existing weight loss approaches and whether anti-diabetic interventions rely on leptin lowering independent of weight loss.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.

Para utilizar esta función, debe iniciar sesión o registrarse

Coordinador

UNIVERSITETET I BERGEN
Aportación neta de la UEn
€ 284 345,28
Coste total
€ 284 345,28

Socios (1)